Closing the gap between clinic and cage: sensori-motor and cognitive behavioural testing regimens in neurotoxin-induced animal models of Parkinson's disease.
Animal models that make use of chemical toxins to adversely affect the nigrostriatal dopaminergic pathway of rodents and primates have contributed significantly towards the development of symptomatic therapies for Parkinson's disease (PD) patients. Although their use in developing neuro-therapeutic and -regenerative compounds remains to be ascertained, toxin-based mammalian and a range of non-mammalian models of PD are important tools in the identification and validation of candidate biomarkers for earlier diagnosis, as well as in the development of novel treatments that are currently working their way into the clinic. Toxin models of PD have and continue to be important models to use for understanding the consequences of nigrostriatal dopamine cell loss. Functional assessment of these models is also a critical component for eventual translational success. Sensitive behavioural testing regimens for assessing the extent of dysfunction exhibited in the toxin models, the degree of protection or improvement afforded by potential treatment modalities, and the correlation of these findings with what is observed clinically in PD patients, ultimately determines whether a potential treatment moves to clinical trials. Here, we review existing published work that describes the use of such behavioural outcome measures associated with toxin models of parkinsonism. In particular, we focus on tests assessing sensorimotor and cognitive function, both of which are significantly and progressively impaired in PD.
Institute for Ageing and Health, Department of Neurology, The University of Newcastle, Newcastle-Upon-Tyne, United Kingdom. ilse-sanet.pienaar@ncl.ac.uk
Ilse S
IS
Pienaar
Bingwei
B
Lu
Timothy
T
Schallert
D000818:Animals; D003072:Cognition Disorders / Q000209:etiology*; D004195:Disease Models, Animal; D020233:Gait Disorders, Neurologic / Q000209:etiology*; D006801:Humans; D009498:Neurotoxins / Q000633:toxicity*; D010300:Parkinson Disease / Q000150:complications* / Q000209:etiology*
D009498:Neurotoxins